Trial Profile
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 16 Feb 2024 Planned End Date changed from 1 Jan 2023 to 1 Jan 2025.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 30 Apr 2021 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2022.